Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India.

IF 3 Q2 ONCOLOGY
JCO Global Oncology Pub Date : 2025-07-01 Epub Date: 2025-07-11 DOI:10.1200/GO-25-00099
Bharath Gangadhar, Chitrakshi Nagpal, Aparna Sharma, Bivas Biswas, Somnath Roy, Aditya Bhagwat, Deepam Pushpam, Sameer Bakhshi, Sunil Kumar, Kunhi Parambath Haresh, Atul Batra
{"title":"Primary Mediastinal Germ Cell Tumors: A Real-World Analysis of Clinical Characteristics, Treatment, and Survival Outcomes From Two Tertiary Cancer Centers in India.","authors":"Bharath Gangadhar, Chitrakshi Nagpal, Aparna Sharma, Bivas Biswas, Somnath Roy, Aditya Bhagwat, Deepam Pushpam, Sameer Bakhshi, Sunil Kumar, Kunhi Parambath Haresh, Atul Batra","doi":"10.1200/GO-25-00099","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Mediastinal germ cell tumors (GCTs) are rare malignancies, predominantly affecting young males, with limited real-world data on treatment outcomes in India. This study aimed to evaluate the clinical characteristics, treatment patterns, and survival outcomes of patients with mediastinal GCTs, emphasizing the effectiveness of first-line chemotherapy regimens.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 81 patients diagnosed with mediastinal GCTs at two tertiary cancer centers in India from 2005 to 2023. Data on demographics, histological subtypes, presenting symptoms, treatment regimens, and outcomes were collected. Kaplan-Meier analysis was used to calculate progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The median age at diagnosis was 26 years, with a male predominance (96.3%). Common histological subtypes included seminoma (34.3%) and yolk sac tumor (31.3%). First-line chemotherapy comprised bleomycin, etoposide, and cisplatin (BEP; 60.5%) and etoposide, ifosfamide, and cisplatin (VIP; 27.8%). Response rates included complete response (25.3%) and partial response (54.4%). After a median follow-up of 15 months, the median PFS and OS were not reached, with 2-year PFS and OS rates of 92.7% and 93.3%, respectively. Seminomas demonstrated better PFS compared with nonseminomatous GCTs (<i>P</i> = .004). Severe toxicities were observed in 48.1% of patients, with febrile neutropenia being the most common.</p><p><strong>Conclusion: </strong>This study highlights the effectiveness of BEP and VIP chemotherapy in achieving high response rates and favorable survival outcomes in mediastinal GCTs. Early diagnosis, appropriate histological classification, and aggressive multimodal treatment strategies are essential for improving long-term outcomes in this predominantly young patient population. Further research is warranted to validate these findings and optimize therapeutic approaches.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"11 ","pages":"e2500099"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-25-00099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Mediastinal germ cell tumors (GCTs) are rare malignancies, predominantly affecting young males, with limited real-world data on treatment outcomes in India. This study aimed to evaluate the clinical characteristics, treatment patterns, and survival outcomes of patients with mediastinal GCTs, emphasizing the effectiveness of first-line chemotherapy regimens.

Methods: A retrospective analysis was conducted on 81 patients diagnosed with mediastinal GCTs at two tertiary cancer centers in India from 2005 to 2023. Data on demographics, histological subtypes, presenting symptoms, treatment regimens, and outcomes were collected. Kaplan-Meier analysis was used to calculate progression-free survival (PFS) and overall survival (OS).

Results: The median age at diagnosis was 26 years, with a male predominance (96.3%). Common histological subtypes included seminoma (34.3%) and yolk sac tumor (31.3%). First-line chemotherapy comprised bleomycin, etoposide, and cisplatin (BEP; 60.5%) and etoposide, ifosfamide, and cisplatin (VIP; 27.8%). Response rates included complete response (25.3%) and partial response (54.4%). After a median follow-up of 15 months, the median PFS and OS were not reached, with 2-year PFS and OS rates of 92.7% and 93.3%, respectively. Seminomas demonstrated better PFS compared with nonseminomatous GCTs (P = .004). Severe toxicities were observed in 48.1% of patients, with febrile neutropenia being the most common.

Conclusion: This study highlights the effectiveness of BEP and VIP chemotherapy in achieving high response rates and favorable survival outcomes in mediastinal GCTs. Early diagnosis, appropriate histological classification, and aggressive multimodal treatment strategies are essential for improving long-term outcomes in this predominantly young patient population. Further research is warranted to validate these findings and optimize therapeutic approaches.

原发性纵隔生殖细胞肿瘤:来自印度两个三级癌症中心的临床特征、治疗和生存结果的真实世界分析。
目的:纵隔生殖细胞肿瘤(gct)是一种罕见的恶性肿瘤,主要影响年轻男性,在印度治疗结果的实际数据有限。本研究旨在评价纵隔gct患者的临床特点、治疗模式和生存结局,强调一线化疗方案的有效性。方法:回顾性分析2005年至2023年印度两家三级癌症中心诊断为纵隔gct的81例患者。收集了人口统计学、组织学亚型、表现症状、治疗方案和结果的数据。Kaplan-Meier分析计算无进展生存期(PFS)和总生存期(OS)。结果:诊断时中位年龄为26岁,男性居多(96.3%)。常见的组织学亚型包括精原细胞瘤(34.3%)和卵黄囊瘤(31.3%)。一线化疗包括博莱霉素、依托泊苷和顺铂(BEP;60.5%)和依托泊苷、异环磷酰胺和顺铂(VIP;27.8%)。缓解率包括完全缓解(25.3%)和部分缓解(54.4%)。中位随访15个月后,中位PFS和OS均未达到,2年PFS和OS率分别为92.7%和93.3%。精原细胞瘤的PFS优于非精原细胞瘤的gct (P = 0.004)。48.1%的患者出现严重毒性反应,以发热性中性粒细胞减少症最为常见。结论:本研究强调了BEP和VIP化疗在纵隔gct中获得高缓解率和良好的生存结局的有效性。早期诊断、适当的组织学分类和积极的多模式治疗策略对于改善以年轻患者为主的患者群体的长期预后至关重要。需要进一步的研究来验证这些发现并优化治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信